Orphan drugs make up a growing slice of the pharmaceutical pipeline, with a significant share of new drug approvals, and payers are taking notice of their increasing market numbers and ultra-expensive price tags. Precision's Jeremy Schafer, PharmD, MBA, discusses how manufacturers may adjust their promotion of orphan drugs to ensure continued market access.
How much of a role can pharmaceutical manufacturers play in the social determinants of health? Industry experts, Maureen Hennessey, PhD, and Dominic Galante, MD, discuss how much they can stand to gain in medication adherence and outcomes from partnering with other industry stakeholders and programs around the issue.
Love them or hate them, copay accumulator programs probably aren't going away anytime soon. We'll have to see how the market evolves over time with manufacturers and payers adapting these programs to counteract each other. The dance continues!
The pharmaceutical industry remained in the headlines last year, although not always for the best reasons. Precision's Andrew Cournoyer, RPh, and Dan Danielson, RPh, MS, give us their takes on the various pharma happenings in 2019.
What are the biggest key takeaways from 2019? In the latest All Access newsletter by Precision for Value we asked our advisors to reflect on the market events for the year by type of payer.